A director at Opko Health Inc bought 580,000 shares at 1.326USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Wednesday, December 3rd at 12:00 p.m. Eastern time. Investors interested in scheduling a meeting with OPKO management should conta...
HCI Group Reports Third Quarter 2025 Results TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- HCI Group, Inc. (NYSE:HCI), reported pre-tax income of $90.6 million and net income of $67.9 million for the third quarter of 2025 compared with pre-tax income of $14.1 million and net income of $9.4 million for the third quarter of 2024. Net income after noncontrolling interests was $65.5 million compared with $5.7 million in the third quarter of 2024. Diluted earnings per share were $4.90 in the third quarter of 2025, compared with $0.52 in the third quarter of 2024. Management Commentary“This w...
OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Regeneron’s...
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that it has entered into a license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to discover and develop multi...
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced the initiation and recent dosing of the first patient in a Phase 1/2a clinical trial () with MDX2004, a first-in-class trispecific antibody-fusion protein for oncology...
HCI Group Sets Third Quarter 2025 Earnings Call for Thursday, November 6, 2025, at 4:45 p.m. ET TAMPA, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- (NYSE: HCI) will hold a conference call on Thursday, November 6, 2025, at 4:45 p.m. Eastern Time to discuss results for the third quarter ended September 30, 2025. Financial results will be issued in a press release the same day after the close of the market. HCI management will host the presentation, followed by a question-and-answer period. Interested parties can listen to the live presentation by dialing the listen-only number below or by cli...
HCI Group Declares Quarterly Cash Dividend TAMPA, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- The board of directors of (NYSE: HCI) has declared a regular quarterly cash dividend in the amount of 40 cents per common share. The dividend is scheduled to be paid December 19, 2025 to shareholders of record at the close of business November 21, 2025. About HCI Group, Inc.HCI Group is a holding company with two distinct operating units. The first unit includes four top-performing insurance companies, a captive reinsurance company, and operations in claims management and real estate. The second un...
OPKO Health to Report Third Quarter 2025 Financial Results on October 29 MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, October 29, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on October 29th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages parti...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Invesco Senior Income Trust and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 14 October 2025 in which we reassessed the appropriateness of the ratings in th...
Exzeo Group, Inc. Launches Initial Public Offering TAMPA, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- HCI Group, Inc. (NYSE:HCI) today announced that its majority owned subsidiary, Exzeo Group, Inc., has launched its initial public offering (“IPO”) pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (the "SEC"). Exzeo is offering 8,000,000 shares of its common stock in the IPO. All shares being offered are primary shares, and HCI Group will retain majority ownership following the IPO. Exzeo intends to grant the underwriters a 30-day option t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.